Wren

Do antidepressants help bipolar lows, and can they bring on a high?

They can help some lows, but the average extra benefit is small and a high can occur during treatment.

Antidepressants are medicines used to lift depression. There is some evidence for adding one to a medicine that protects against highs, usually after better-established choices have given too little relief. The person's earlier highs, the particular antidepressant and any high symptoms during the low shape that choice. Continuing after recovery may reduce returning lows, but the effects on highs and on staying well overall remain uncertain.⁠

How much relief from a low to expect

Trials give a mixed picture of the extra relief an antidepressant brings. A review of trials found a small average benefit when an antidepressant was added to existing treatment, while several individual trials found little extra improvement. That makes an antidepressant a possible later option when better-established treatments for a low have given too little relief.⁠

In one trial of 366 people with bipolar depression, everyone was already taking a medicine to stabilise mood. Around 24 in every 100 people given an added antidepressant had eight consecutive weeks of stable mood, compared with around 27 in every 100 given an added dummy pill, which contains no active medicine. Treatment lasted up to 26 weeks. Recovery and the frequency of highs were similar in the two groups. This illustrates how uncertain the extra benefit can be even over several months of treatment.⁠

Bipolar I and bipolar II

Bipolar I includes a history of mania, a high that seriously affects judgement or ordinary life. Bipolar II includes hypomania, a milder high, and depression, with no past mania. Bipolar I and II explains the difference. The Canadian and international guideline advises against an antidepressant as the sole medicine for a bipolar I low. For bipolar II, sertraline and venlafaxine are later choices mainly for lows without accompanying high symptoms.⁠

Antidepressants differ in their evidence for bipolar lows. The guideline describes some benefit from adding certain antidepressants, including bupropion. A trial of another antidepressant, paroxetine, taken alone found little help with bipolar II depression. Choosing among antidepressants therefore includes the evidence for that medicine and the person's previous response.⁠

A sixteen-week trial of 142 people with bipolar II depression compared lithium, a medicine used for highs, lows and prevention, with the antidepressant sertraline and with both together. Depression improved in a similar proportion of people in each group. Around 14 in every 100 participants developed a high during treatment; all these highs were hypomania, with similar rates across the three groups. Most happened in the first five weeks. Taking both medicines brought more people to leave treatment early and similar speed of improvement. Living with lithium explains taking that medicine.⁠

The trial compared active treatments, so it helps weigh the improvement, emerging highs and treatment burden seen with these options. The guideline gives a different place to sertraline in bipolar II than in bipolar I because the history of highs and the evidence available differ.⁠

How much risk of a high to expect

Moving from depression into mania or hypomania during treatment is often called a mood switch. Bipolar can move between lows and highs as part of its own course, and antidepressant treatment can contribute to that change. Comparing people given an antidepressant with people given a dummy pill helps estimate the added risk.⁠

The review brought together thirteen trials with 1,362 people. In the short trials comparing antidepressants with dummy pills, the frequency of highs was similar on average, offering some reassurance about treatment over the first few weeks. The estimates were too imprecise for confidence about an individual medicine's added risk, and the longest trials lasted ten weeks. Most participants were taking an antidepressant alongside another medicine, so this reassurance carries most strongly to that use.⁠

Venlafaxine deserves particular care. Two trials comparing it with other antidepressants found more highs with venlafaxine. The combined review also placed it at the higher-risk end, although the size of that difference remains uncertain. A previous high after an antidepressant is especially important when weighing another trial of treatment.⁠

The guideline favours avoiding antidepressants, or using them cautiously when needed, after a previous antidepressant-related high, during a mixed state, when low and high symptoms occur together, or after recent rapid cycling, meaning at least four mood episodes in a year. Mixed states in bipolar and Rapid cycling in bipolar explain those patterns. Those personal patterns make close review especially important even when average trial results look reassuring.⁠

Continuing after a low lifts

One trial followed 177 people with bipolar I whose depression had lifted while taking escitalopram or bupropion alongside their other treatment. It compared continuing the antidepressant for a year with changing to a dummy pill after eight weeks.⁠

Over the year, depression returned in around 17 in every 100 people who continued, compared with around 40 in every 100 who stopped after eight weeks. Highs occurred in around 12 in every 100 who continued, compared with around six in every 100 who stopped. The estimate for the difference in highs was uncertain. For the trial's overall measure of another mood episode or serious mood worsening, the figures were around 31 in every 100 and 46 in every 100. The overall benefit remained uncertain, and the trial stopped before recruiting enough people, owing to slow recruitment and limited funding.⁠

These findings give a reason to review continuing treatment once a low has lifted. Someone who has had repeated lows and clear benefit may place more weight on keeping depression away; someone whose sleep and energy have begun moving towards a high has a different balance to weigh. That choice brings the person's course together with the trial's differing effects on lows and highs.⁠

Arranging treatment and a review

An antidepressant is a possible later treatment for a bipolar low, usually alongside a medicine that protects against highs. The modest expected benefit, side effects, previous response and history of highs all belong in the treatment discussion. Working out a choice about bipolar medicine gives prompts for preparing it. An agreed review can look at both relief from depression and changes in sleep, energy and activity, then return to the question of continuing once the low has lifted.⁠

Sleeping much less while feeling unusually energetic, faster thoughts or a marked rise in activity during treatment calls for prompt contact with the prescriber, the professional responsible for the prescription, because the antidepressant may need stopping and the high needs assessment. The agreed plan records that response and who to contact, so the person and someone close have a next step ready.⁠

Related: Antidepressants in bipolar · Medicines for bipolar · Making an early-warning and action plan.

Sources

  1. 1Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder Canadian and international guideline
  2. 2The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence Guideline update
  3. 3Duration of Adjunctive Antidepressant Maintenance in Bipolar I Depression. Continuation trial
  4. 4Effectiveness of adjunctive antidepressant treatment for bipolar depression. Antidepressant trial
  5. 5Switch Rates During Acute Treatment for Bipolar II Depression With Lithium, Sertraline, or the Two Combined: A Randomized Double-Blind Comparison. Bipolar II trial
  6. 6Switch to mania after acute antidepressant treatment for bipolar depression: a systematic review and network meta-analysis of randomised controlled trials 2025 review

Last updated 12 October 2026